129 related articles for article (PubMed ID: 11135082)
1. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.
Ruggenenti P; Pagano E; Tammuzzo L; Benini R; Garattini L; Remuzzi G
Kidney Int; 2001 Jan; 59(1):286-94. PubMed ID: 11135082
[TBL] [Abstract][Full Text] [Related]
2. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
[TBL] [Abstract][Full Text] [Related]
3. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
[TBL] [Abstract][Full Text] [Related]
4. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1.
Perna A; Ruggenenti P; Testa A; Spoto B; Benini R; Misefari V; Remuzzi G; Zoccali C
Kidney Int; 2000 Jan; 57(1):274-81. PubMed ID: 10620209
[TBL] [Abstract][Full Text] [Related]
5. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.
Ruggenenti P; Perna A; Remuzzi G
J Am Soc Nephrol; 2001 Dec; 12(12):2832-2837. PubMed ID: 11729254
[TBL] [Abstract][Full Text] [Related]
6. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
[TBL] [Abstract][Full Text] [Related]
7. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.
Ruggenenti P; Perna A; Benini R; Bertani T; Zoccali C; Maggiore Q; Salvadori M; Remuzzi G
J Am Soc Nephrol; 1999 May; 10(5):997-1006. PubMed ID: 10232685
[TBL] [Abstract][Full Text] [Related]
8. Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen).
Ruggenenti P; Perna A; Zoccali C; Gherardi G; Benini R; Testa A; Remuzzi G
J Am Soc Nephrol; 2000 Jan; 11(1):88-96. PubMed ID: 10616844
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.
Ruggenenti P; Perna A; Lesti M; Pisoni R; Mosconi L; Arnoldi F; Ciocca I; Gaspari F; Remuzzi G
Kidney Int; 2000 Nov; 58(5):2093-101. PubMed ID: 11044230
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
Schädlich PK; Brecht JG; Brunetti M; Pagano E; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2001; 19(5 Pt 1):497-512. PubMed ID: 11465309
[TBL] [Abstract][Full Text] [Related]
12. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
Ruggenenti P; Perna A; Gherardi G; Gaspari F; Benini R; Remuzzi G
Lancet; 1998 Oct; 352(9136):1252-6. PubMed ID: 9788454
[TBL] [Abstract][Full Text] [Related]
13. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
[TBL] [Abstract][Full Text] [Related]
14. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.
Toto RD; Adams-Huet B; Fenves AZ; Mitchell HC; Mulcahy W; Smith RD
Am J Kidney Dis; 1996 Dec; 28(6):832-40. PubMed ID: 8957034
[TBL] [Abstract][Full Text] [Related]
15. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).
Ruggenenti P; Perna A; Benini R; Remuzzi G
J Am Soc Nephrol; 1998 Nov; 9(11):2096-101. PubMed ID: 9808096
[TBL] [Abstract][Full Text] [Related]
16. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
Ruggenenti P; Perna A; Loriga G; Ganeva M; Ene-Iordache B; Turturro M; Lesti M; Perticucci E; Chakarski IN; Leonardis D; Garini G; Sessa A; Basile C; Alpa M; Scanziani R; Sorba G; Zoccali C; Remuzzi G;
Lancet; 2005 Mar 12-18; 365(9463):939-46. PubMed ID: 15766995
[TBL] [Abstract][Full Text] [Related]
17. Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.
Seeman T; Dusek J; Vondrák K; Flögelová H; Geier P; Janda J
Am J Hypertens; 2004 May; 17(5 Pt 1):415-20. PubMed ID: 15110900
[TBL] [Abstract][Full Text] [Related]
18. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
Chiurchiu C; Remuzzi G; Ruggenenti P
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S58-63. PubMed ID: 15938036
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
Pisoni R; Faraone R; Ruggenent P; Remuzzi G
J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
